The effect of a 5-HT1A receptor agonist on striatal dopamine release

Synapse

Volumn 57, Issue 2, 2005, Pages 67-75

  Bantick, R Alexander ^a   De Vries, Michiel H ^b   Grasby, Paul M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

5 HT1A receptor; Anticataleptic; Dopamine; Flesinoxan; PET scanning; Raclopride

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLESINOXAN; GROWTH HORMONE; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; RACLOPRIDE; RADIOLIGAND; SEROTONIN 1A AGONIST; CARBON; DOPAMINE RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ADULT; ARTICLE; CATALEPSY; CORPUS STRIATUM; DIZZINESS; DOPAMINE RELEASE; HEADACHE; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALE; NAUSEA; NIGRONEOSTRIATAL SYSTEM; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SEROTONIN RELEASE; SOMNOLENCE; BINDING COMPETITION; BLOOD; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY; REFERENCE VALUE; SCINTISCANNING; SECRETION; UPREGULATION;

ADULT; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CATALEPSY; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; SEROTONIN; SEROTONIN AGONISTS; UP-REGULATION;

EID: 21344473857     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20156     Document Type: Article

References (72)

1. Andersen HL, Kilpatrick IC. 1996. Prevention by (±)-8-hydroxy-2- (di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br J Pharmacol 118:421-427.
2. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347:353-362.
3. Arborelius L, Nomikos GG, Hacksell U, Svensson TH. 1993b. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148:465-466.
4. 1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35-46.
5. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46.
6. 1A receptor. Neuropsychopharmacology 29:847-859.
7. Barnes NM, Sharp T. 1999. A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
8. Barradell LB, Fitton A. 1996. Tandospirone. CNS Drugs 5:147-153.
9. Benloucif S, Galloway MP. 1991. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200:1-8.
10. Benloucif S, Keegan MJ, Galloway MP. 1993. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265:373-377.
11. Bloomfield PM, Spinks TJ, Reed J, Schnorr L, Westrip AM, Livieratos L, Fulton R, Jones T. 2003. The design and implementation of a motion correction scheme for neurological PET. Phys Med Biol 48:959-978.
12. 1B agonists: involvement of the hippocampo-accumbens pathway. Neuropharmacology 35:1521-1529.
13. Brody D, Adler LA, Kim T, Angrist B, Rotrosen J. 1990. Effects of buspirone in seven schizophrenic subjects [letter]. J Clin Psychopharmacol 10:68-69.
14. 2 sites. Neuroscience 28:275-290.
15. Chen NH, Reith ME. 1995. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 64:1585-1597.
16. Christoffersen CL, Meltzer LT. 1998. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18:399-402.
17. Crino PB, Vogt BA, Volicer L, Wiley RG. 1990. Cellular localization of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat. J Pharmacol Exp Ther 252:651-656.
18. de Koning P, de Vries MH. 1995. A comparison of the neuro- endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol 39:7-14.
19. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 121:1-26.
20. 1A receptor agonist, alnespirone (S-20499), affecting dopaminergic systems in the rat brain? Eur J Pharmacol 350:171-180.
21. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. 1991. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11:193-197.
22. Golembiowska K, Wedzony K. 1993. Enhancement by ipsapirone of dopamine release in the rat striatum. Pol J Pharmacol 45:299-308.
23. 1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology 34:1311-1326.
24. 11C]WAY-100635. Brain Res 745:96-108.
25. Hall MD, el Mestikawy S, Emerit MB, Pichat L, Hamon M, Gozlan H. 1985. [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J Neurochem 44:1685-1696.
26. 11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 19:210-217.
27. Ichikawa J, Meltzer HY. 1999. The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens. Brain Res 842:445-451.
28. Ichikawa J, Meltzer HY. 2000. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252-263.
29. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518.
30. 1A receptor. Eur J Pharmacol 441:137-140.
31. Kapur S, Remington G. 1996. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476.
32. Kelland MD, Freeman AS, Chiodo LA. 1990. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253:803-811.
33. Knable MB, Weinberger DR. 1997. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123-131.
34. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
35. Lamelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
36. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249.
37. 1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. Neuropharmacology 45:1057-1069.
38. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl) 131:57-63.
39. Lucas G, De Deurwaerdere P, Caccia S, Umberto S. 2000. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39:1053-1063.
40. 2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
41. 1A receptors. J Pharmacol Exp Ther 295:853-861.
42. Moss LE, Neppe VM, Drevets WC. 1993. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13:204-209.
43. Neal-Beliveau BS, Joyce JN, Lucki I. 1993. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217.
44. 35S]GTPγS binding study. Eur J Pharmacol 355:245-256.
45. 2 receptors. J Neurosci Res 55:600-607.
46. 1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transm Gen Sect 103:541-554.
47. 1A receptor agonist flesinoxan in normal volunteers. Psychopharmacology (Berl) 164:27-32.
48. Pitchot W, Wauthy J, Legros JJ, Ansseau M. 2004. Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study. Eur Neuropsychopharmacol 14:151-155.
49. Poyurovsky M, Weizman A. 1997. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int Clin Psychopharmacol 12:263-268.
50. 1A receptor agonist properties. Eur J Pharmacol 356:189-192.
51. 1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav Pharmacol 11:299-305.
52. 1A receptors. Eur J Pharmacol 395:143-147.
53. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221.
54. 1A agonist ±8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18:218-224.
55. 2C receptor antagonist. Br J Pharmacol 126:572-574.
56. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129:1028-1034.
57. Santiago M, Matarredona ER, Machado A, Cano J. 1998. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 52:591-598.
58. 1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Neuropsychopharmacology 13:93-104.
59. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr Ann 26:88-92.
60. 11C]raclopride and PET in normal human subjects. Am J Psychiatry 154:490-496.
61. Solvay Pharmaceuticals. 1997. Investigational drug brochure: flesinoxan. HCl capsules. Weesp, The Netherlands: Solvay Pharmaceuticals.
62. Spinks TJ, Jones T, Bloomfield PM, Bailey DL, Miller M, Hogg D, Jones WF, Vaigneur K, Reed J, Young J, Newport D, Moyers C, Casey ME, Nutt R. 2000. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol 45:2601-2618.
63. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Karachi M, Sumiyoshi C, Jayathilake K, Meltzer HY. 2001a. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725.
64. 1A agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868.
65. Tanda G, Carboni E, Frau R, Di Chiara G. 1994. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115:285-288.
66. Tiihonen J, Kuoppamaki M, Nagren K, Bergman J, Eronen E, Syvalahti E, Hietala J. 1996. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 126:277-280.
67. 1A receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci 14:81-86.
68. 11C]raclopride. Neuropsychopharmacology 20:424-433.
69. Wadenberg ML. 1996. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339.
70. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34:495-499.
71. Yoshida K, Sugita T, Higuchi H, Hishikawa Y. 1998. Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13:421-422.
72. Zhang J, Freeman AS. 1993. Electrophysiological effects of the selective 5-HT-1A agonist, 8-OH-DPAT, on midbrain DA neurones: A9/ A10 differences [Abstract]. Soc Neurosci Abstr 19:1373.